In addition to facilitating SIK2 degradation, this compound decreases RAD50 phosphorylation, impairs the nuclear translocation of RAD50, and when used with PARP inhibitors, has a synergistic cytotoxic effect on ovarian cancer [20]. Here, SIK2 is linked to ovarian carcinoma.